Endotis Pharma Presents Data On The Neutralizable Anticoagulant EP217609 In An Extracorporeal Circulation Model

Biocitech Park, Paris (France), June 3rd, 2010. Endotis Pharma announced that initial results on the neutralizable anticoagulant EP217609 in a canine model of extracorporeal circulation (ECC) will be presented today, at the French Society of Thoracic and Cardiovascular Surgery's 63th annual meeting in Tours, France.

Both EP217609 and its specific antidote avidin were well tolerated in this clinically relevant animal study. A single dose of EP217609 resulted in efficient, stable anticoagulation throughout the ECC procedure. Subsequent administration of avidin produced rapid, complete, irreversible neutralization and no rebound effect. There was no evidence of clotting in the extracorporeal circuits.